Nachman illustrated the details of three different types of vaccines being implemented in clinical trials of treatment for COVID-19. Among them were the mRNA vaccine being utilized and distributed by pharmaceutical giants Moderna and Pfizer; the nonreplicating viral vector vaccine created by the English-based pharmaceutical company AstraZeneca; and the protein plus vaccine developed by Novavax — an American vaccine development corporation. With each explanation, she walked the listeners through the process of how the vaccines are administered, their chemical components and any complications or potential side effects. According to SBU, the most common symptoms shown in those who received both doses of the Pfizer vaccines were fatigue and headache. "Information is available on the Stony Brook website if anyone is interested in enrolling," Nachman said. "However, the clock is ticking. We're enrolling about 5,000 patients per week."